Wasatch Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History

Wasatch Advisors’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$21.5M	Buy	2,942,432 +1,635,185	+125%	+$15.4M	0.16%	111
2026 Q2	$14.2M	Sell	1,307,247 -33,669	-3%	-$384K	0.09%	128
2026 Q1	$14.9M	Buy	1,340,916 +9,247	+0.7%	+$117K	0.1%	118
2025 Q4	$22.1M	Sell	1,331,669 -205,549	-13%	-$2.94M	0.13%	122
2025 Q3	$18.1M	Buy	1,537,218 +75,323	+5%	+$777K	0.1%	132
2025 Q2	$14M	Sell	1,461,895 -239,732	-14%	-$1.33M	0.07%	141
2025 Q1	$10.7M	Buy	1,701,627 +142,699	+9%	+$866K	0.06%	156
2024 Q4	$12.7M	Buy	1,558,928 +1,311,986	+531%	+$16.2M	0.06%	152
2024 Q3	$4.46M	Buy	+246,942	New	+$3.45M	0.02%	196

Other funds holding PHAT

Medicxi Ventures Management St. Helier, Jersey $127M AUM 21.77% 1-Year Est. Return

Catalys Pacific Tokyo, Japan $210M AUM 33.18% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Kornitzer Capital Management Shawnee Mission, Kansas $4.8B AUM 30.14% 1-Year Est. Return

Penn Mutual Asset Management Conshohocken, Pennsylvania $23.1M AUM 4.22% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Wasatch Advisors's PHAT Position: Q3 2026 in Review

Wasatch Advisors increased its Phathom Pharmaceuticals (PHAT) stake by 125% in Q3 2026, buying an estimated $15.4M and bringing the position to 2,942,432 shares worth $21.5M. The position accounts for 0.16% of the portfolio, ranked #111.

Wasatch Advisors first reported a position in PHAT in Q3 2024 and has held it in 9 quarters since. The position peaked at $22.1M in Q4 2025. 33 funds tracked by Wall St. Rank hold PHAT as of Q3 2026.

Wasatch Advisors held 2,942,432 shares of Phathom Pharmaceuticals worth $21.5M as of Q3 2026.
Wasatch Advisors bought 1,635,185 Phathom Pharmaceuticals shares in Q3 2026, an estimated $15.4M.
Phathom Pharmaceuticals made up 0.16% of Wasatch Advisors's portfolio in Q3 2026, its #111 holding.
Wasatch Advisors first reported a position in Phathom Pharmaceuticals in Q3 2024 and has held it in 9 quarters since.
Wasatch Advisors's Phathom Pharmaceuticals position peaked at $22.1M in Q4 2025.
33 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2026.

Based on Wasatch Advisors's 13F filing for Q3 2026, filed 13 Oct 2026.